The combination of immunotherapy (49), chemotherapy (50, 51), or EGFR TKI (50) with antiangiogenic therapy in previous researches showed promising antitumor activity in pre-treated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.